IDH1 and acute myeloid leukemia: For patients with a good (CEBPa double mutant, CEBPa-bZIP, or core-binding factor AML) or intermediate-risk profile, without FLT3 or IDH1/2 mutations, standard 7 + 3 induction treatment results in CR in 60–70% of patients and is therefore a valid treatment option [29].